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ABSTRACT
Regulation of the positive transcription elongation
factor, P-TEFb, plays a major role in controlling
mammalian transcription and this is accomplished
in part by controlled release of P-TEFb from the 7SK
snRNP that sequesters the kinase in an inactive
state. We demonstrate here that a similar P-TEFb
control system exists in Drosophila. We show that
an RNA previously suggested to be a 7SK homo-
log is, in fact, associated with P-TEFb, through
the action of a homolog of the human HEXIM1/2
proteins (dHEXIM). In addition, a Drosophila La
related protein (now called dLARP7) is shown to
be the functional homolog of human LARP7. The
Drosophila 7SK snRNP (d7SK snRNP) responded
to treatment of cells with P-TEFb inhibitors and to
nuclease treatment of cell lysates by releasing
P-TEFb. Supporting a critical role for the d7SK
snRNP in Drosophila development, dLARP7
and dHEXIM were found to be ubiquitously
expressed throughout embryos and tissues at all
stages. Importantly, knockdown of dHEXIM was
embryonic lethal, and reduction of dHEXIM in
specific tissues led to serious developmental
defects. Our results suggest that regulation of
P-TEFb by the d7SK snRNP is essential for the
growth and differentiation of tissues required
during Drosophila development.
INTRODUCTION
The highly orchestrated pattern of gene expression driving
cellular differentiation and tissue development is to a large
extent controlled at the level of transcription, and regula-
tion of the elongation phase of transcription plays an
important role. RNA polymerase II elongation control
starts with the default action of negative factors including
DRB sensitivity inducing factor (DSIF) and negative
elongation factor (NELF) that block the movement of
initiated polymerases into the body of genes (1). These
promoter proximal paused polymerases are poised for a
regulated release into productive elongation by the
positive transcription elongation factor, P-TEFb (2). The
cyclin-dependent kinase activity of P-TEFb (3) coordin-
ates the modiﬁcation and exchange of factors associated
with the elongation complex. The large subunit of DSIF,
Spt5, as well as the NELFe subunit is phosphorylated by
P-TEFb triggering the release of NELF from the complex
(4–6). DSIF remains in the transcription complex and is
joined by factors that dramatically change the rate of
elongation from essentially zero to an average rate of
 3.8kb/min (6,7). The P-TEFb-mediated transition into
productive elongation is a singular event occurring near
every gene’s 50-end that commits the engaged polymerase
to complete an mRNA.
A large body of evidence points to RNA polymerase II
elongation control as a general process required for the
biogenesis of essentially all mRNAs. Treatment of cells
with P-TEFb inhibitors blocks mRNA production (8) and
mosttranscriptionbyRNApolymeraseIIinnucleiisolated
from the cells (9) and the process is reproduced utilizing
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lian nuclear extracts (2,11) regardless of the identity of the
promoter used. Strong support for the generality of the
process was found in the results of ChIP-Seq analyses that
pinpointedthepositionofRNApolymeraseIIacrossmam-
malian and Drosophila genomes (12). Promoter proximal
paused polymerases were found on a large number of
Drosophila genes (13,14) and on most mammalian genes
(6,15,16). These included not only genes expressed at
moderate to high levels of expression, but also genes with
very low expression. The implication of these studies is
that P-TEFb mediated release of the poised polymerases
into productive elongation could be the rate limiting step
of transcription on a large fraction of genes. Together all
evidence points to P-TEFb not only being required for
mRNA production, but also suggest that directed
P-TEFb action could be a principle regulated step (17). In
fact, c-myc which is a major regulator of many genes has
beendemonstratedtofunctionatthelevelofelongation(6).
Because of the critical role that P-TEFb plays in
regulating gene expression metazoans have developed a
complex regulatory system that involves controlled
sequestration and release of P-TEFb from an inhibitory
complex (18,19). This complex is built on a 7SK snRNA
scaffold (20) that constitutively contains a La related
protein, LARP7 (21–23). 7SK is one of a few snRNAs
that are capped by the addition of a single methyl group
on the gamma phosphate on the 50-end of the RNA (24).
The methyl phosphate capping enzyme MEPCE respon-
sible for the modiﬁcation is also an integral part of the
7SK snRNP (21,25,26). In HeLa cells, about half of the
7SK snRNP contains these two proteins along with a het-
erogeneous array of hnRNP proteins (21,27,28). In the
other half of the 7SK snRNPs, the hnRNPs are replaced
by a double-stranded RNA-binding protein, HEXIM1 or
HEXIM2 and this protein interacts with and inhibits
P-TEFb (29–32). Both of the 7SK snRNPs distinguish
themselves from all other snRNPs by being readily ex-
tracted from mild detergent treated nuclei at low salt
indicating that they are not tightly bound to chromatin
(33). The P-TEFb not in the 7SK snRNP, on the other
hand, is only extracted by higher salt, indicating that it is
associated with chromatin and suggesting that it is
actually engaged in functional interactions (33). These bio-
chemical properties suggest that P-TEFb could be
extracted from the 7SK snRNP at the precise time and
location needed to activate expression of speciﬁc genes.
Two proteins have been demonstrated to directly cause
release of P-TEFb from the 7SK snRNP. One is HIV-1
Tat, a virally encoded transactivator which was the ﬁrst
protein found to functionally interact with P-TEFb (34).
A crystal structure of Tat bound to P-TEFb revealed an
extensive, stable interface between the viral and host
protein (35). Tat also has an RNA-binding domain with
speciﬁcity toward the nascent HIV transcript, TAR, which
ultimately results in recruitment of P-TEFb and activation
of viral transcription (36). Expression of Tat alone in
human cells leads to the release of P-TEFb from the
7SK snRNP (37). This release does not require any modi-
ﬁcations of Tat or the proteins or RNA in the 7SK snRNP
because recombinant Tat can extract P-TEFb from highly
puriﬁed 7SK snRNPs immunoprecipitated from cell
extracts (38). Although Tat interacts directly with the
7SK RNA and the RNA-binding domain of Tat has a
modest effect on the release of P-TEFb from the 7SK
snRNP, the P-TEFb-binding domain is sufﬁcient for efﬁ-
cient release (37,38). The second protein, Brd4, is a
bromodomain-containing protein that binds to acetylated
histones normally associated with active regions of tran-
scription (39). Brd4 can be found in complex with P-TEFb
and this is mediated by a small domain found in the
C-terminus of Brd4 (40). Just like Tat, this domain leads
to the release of P-TEFb from the 7SK snRNP when ex-
pressed in human cells (38). Furthermore, it can also
extract P-TEFb directly from the immunoprecipitated
7SK snRNPs (38). Because Brd4 does not have an
RNA-binding domain it is clear that P-TEFb binding is
the key property required. A number of other transcrip-
tion factors can interact with P-TEFb and some of them
may also have the ability to extract P-TEFb from the 7SK
snRNP (1). The fact that at least some factors have the
ability to extract P-TEFb provides additional support for
a model in which the P-TEFb used to activate a gene is
taken directly from the 7SK snRNP. This would guard
against accidental activation of poised polymerases on
genes that should be silent while maintaining a relatively
high level of P-TEFb in a potentially active state.
Drosophila is an excellent model system to examine the
role that RNA polymerase II elongation control takes in
regulating development. P-TEFb was ﬁrst identiﬁed in
Drosophila (2) and ﬂy HSP70 genes were among the ﬁrst
genes shown to have promoter proximal paused polymer-
ase (41). Elegant studies from several labs have
demonstrated that these poised polymerases are prevalent
across the ﬂy genome and are especially enriched on
developmentally controlled genes (13,14,42,43). The
rapid induction provided by poised polymerases is useful
in synchronous activation of particular genes across a
population of cells (43,44) and they also can act as insu-
lators when placed between enhancers and another
promoter (45). Unfortunately, only a little is known
about the 7SK snRNP in Drosophila. One study identiﬁed
a potential candidate for 7SK RNA (46) and
another demonstrated that the MEPCE homolog, Bin3,
was associated with and stabilized the RNA (26). Impor-
tantly, it was not determined if P-TEFb was associated
with the RNA. We provide conclusive evidence here that
the RNA identiﬁed is indeed 7SK and that a Drosophila
7SK snRNP containing homologs of human P-TEFb,
HEXIM1/2 and LARP7 exists. We also show that
dHEXIM is essential for development and that the
snRNP is widely expressed. Taken altogether, this
suggests an important role of snRNP in development.
MATERIALS AND METHODS
Cell lines and compounds
Drosophila melanogaster Kc cells were maintained in
T-150 tissue culture ﬂasks in Hyclone SFX-Insect
(Thermo Scientiﬁc) at 25 C between 1 10
6 and
1 10
7cells/ml. In some cases, they were transferred to
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6 and
1 10
7cells/ml, and used for experiments at
4–6 10
6cells/ml. DRB was purchased from Sigma.
Stock solutions were 50mM in EtOH and cells were
treated at a ﬁnal concentration of 100mM. Stocks of
10mM ﬂavopiridol were prepared in DMSO and cells
were treated at a ﬁnal concentration of 500nM. All
stocks were aliquoted at stored at  80 C.
Antibodies
Antibodies to Cyclin T, dHEXIM, and dLARP7 were
generated in sheep by Elmira Biologicals, Inc. (Iowa
City, IA, USA) using the corresponding recombinantly
expressed and puriﬁed proteins. Following testing of
pre-immune, ﬁrst and second bleed antisera for each
antibody, they were afﬁnity puriﬁed using the puriﬁed re-
combinant proteins coupled to actigel-ALD resin accord-
ing to the manufacturer’s protocol (Sterogene).
Cloning and expression of the C-terminal region of
Cyclin T (751–1097)
Following PCR ampliﬁcation of the C-terminal region of
Drosophila Cyclin T (amino acids 751–1097) using primers
to incorporate a 50 NdeI site (CATATGCGAGAAAAGC
TTCGCAAGCTGG) and a 30 XhoI site (CTCGAGCTT
CTTGTTGTAGACGGGCATGGG), the insert was
subcloned into the pCR2.1-TOPO PCR cloning vector
(Invitrogen). Subsequent restriction digest using NdeI
and XhoI and ligation into the pET21a vector yielded
the pET21a-CycT(751–1097) expression vector, which
was veriﬁed by sequencing.
His-tagged Cyclin T (751–1097) protein used for gener-
ation of antibodies was expressed in Escherichia coli BL21
(DE3). After induction of 4 1l cultures with IPTG and
overnight growth at 18 C, cells were sonicated in PBS with
1% Triton X-100, 0.1% saturated solution of PMSF in
isopropanol, 5mM imidazole and protease inhibitors
(Roche), and cleared by spinning for 50min at 200000g.
The lysate was brought to 1M NaCl and then added to
2ml of Ni-NTA resin (Qiagen) that had been
pre-equilibrated with lysis buffer containing 1M NaCl.
After a 1h incubation at 4 C, the ﬂow-through was col-
lected, and the resin was washed with 10 volumes of High
Salt Wash buffer [10mM Tris (pH 7.8), 1M NaCl, 1%
Triton X-100, 0.1% PMSF, 35mM imidazole] and 10
volumes of Low Salt Wash buffer [10mM HEPES (pH
7.8), 70mM KCl, 1% Triton X-100, 0.1% PMSF,
35mM imidazole]. The column was eluted with 4
volumes of Elution Buffer [10mM HEPES (pH 7.8), 1%
Triton, 70mM KCl, 250mM imidazole, 0.1% freshly
added PMSF saturated in isopropanol]. The protein was
then loaded onto a 1ml Mono S column, which was eluted
with a 20ml linear gradient from 70mM to 1M HKEDP
[25mM HEPES (pH 7.6), 70–1000mM KCl, 0.1mM
EDTA, 1mM DTT, 1mM PMSF] and fractions were
stored at  80 C.
Cloning and expression of dHEXIM proteins
A pOT2 plasmid containing the cDNA for dHEXIM
(CG3508, isoform A) was obtained from the Drosophila
Genomics Resource Center (Bloomington, IN, USA).
Following PCR ampliﬁcation of the dHEXIM gene
using primers to incorporate a 50 NdeI site (CATATGG
CTGAAGCTGTAAAAAATGAAAGTG) and a 30 XhoI
site (CTCGAGTTTGACAACTGCATCGGCTGGC),
the insert was subcloned into the pSC-A PCR cloning
vector (Stratagene). Subsequent restriction digest using
NdeI and XhoI and ligation into the pET21a vector
yielded the pET21a-dHEXIM expression vector, which
was veriﬁed by sequencing.
dHEXIM containing a mutation in the RNA-binding
domain (KHRR to ILAA) was created using the
QuikChange site-directed mutagenesis kit (Stratagene).
Forward (CGGGAATGCCGAAGAGGATACTTGCG
GCGGGAAAAAAATCCAAGATGCAGCCC) and
reverse (GGGCTGCATCTTGGATTTTTTTCCCGCC
GCAAGTATCCTCTTCGGCATTCCCG) primers tar-
geting the region were designed to introduce six mutations
changing the KHRR residues to ILAA. These primers
were added to 50ng of pET21a-dHEXIM template and
18 cycles of PCR using Pfu Turbo were used to generate
plasmid with the desired mutations. Following digestion
of methylated parental pET21a-dHEXIM by DpnI,
pET21a-dHEXIM(ILAA) was ampliﬁed and isolated
from E. coli.
His-tagged dHEXIM and dHEXIM(ILAA) proteins
used for generation of antibodies and EMSA were
expressed in E. coli BL21 (DE3) using the same protocol
described above for the puriﬁcation of Cyclin
T (751–1097) except that the low salt wash buffer con-
tained 25mM instead of 35mM imidazole.
Cloning and expression of dLARP7
The clone, LD09531, for Drosophila MXC (dLARP7)
protein was obtained from the Drosophila Genomics
Research Center. The dLARP7 coding region was
cloned into a pET21a (Novagene) expression vector with
a C-terminal histidine tag and the clone was veriﬁed by
sequencing. His-tagged dLARP7 used for generation of
antibodies was expressed in E. coli BL21 (DE3) using
the same protocol described above for the puriﬁcation of
Cyclin T (751–1097) except that the protein ﬂowed
through Mono S. The Mono S ﬂowthrough was loaded
onto a 1ml Mono Q column, which was eluted with a
linear gradient from 70mM to 1M HKEDP [25mM
HEPES (pH 7.6), 70–1000mM KCl, 0.1mM EDTA,
1mM DTT, 1mM PMSF] and fractions were stored
at  80 C.
Cloning and T7 transcription of d7SK
Kc cell genomic DNA was isolated using the Genomic-tip
500 kit (Qiagen). The d7SK gene was PCR-ampliﬁed from
100ng of genomic DNA using primers targeting the pre-
dicted 50 (TAATACGACTCACTATAGGAAGTGTAT
TCTGTGATTG) and 30 (AAAAGAATGGGCAAATT
GCTCGGCA) ends of the 444nt d7SK gene and
incorporating a 50 T7 promoter, and subsequently cloned
into the PCR2.1-TOPO PCR cloning vector (Invitrogen)
and conﬁrmed by sequencing.
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was ampliﬁed from the PCR2.1-d7SK plasmid using the
cloning primers. Transcription was carried out using the
T7 transcription kit from Promega following the manu-
facturer’s protocols. For cold d7SK RNA, 3mg of DNA
template were mixed with 0.5mM NTPs and 40U of T7
RNA polymerase, and incubated for 2h at 37 C. For high
speciﬁc activity RNA probes used for EMSAs, 1mgo f
DNA template was mixed with 0.5mM rATP, rTTP,
and rGTP, 12mM cold rCTP, 20mCi of a-
32P-rCTP, and
20U of T7 RNA polymerase, and incubated for 1h at
37 C. Following transcription, the DNA template was
degraded using DNase I and the RNA was puriﬁed
using the RNeasy kit from Qiagen.
Western blotting
Samples for western blotting were resolved by 9%
polyacryalmide SDS–PAGE and the proteins were then
electroblotted to a 0.45mm nitrocellulose membrane
using an Owl semi-dry transfer apparatus. After being
blocked in 10% non-fat dry milk for 30min, the mem-
branes were incubated in 2.5% milk with 1:1000 dilutions
of afﬁnity-puriﬁed a-Cyclin T, a-dHEXIM, or a-dLARP7
as indicated overnight at 4 C. Following incubation in
2.5% milk containing a 1:15000 dilution of HRP-
conjugated a-sheep secondary antibody (Sigma) for 2h
at room temperature, the blots were developed with
Super Signal Dura West (Pierce) and imaged with a
cooled CCD camera (UVP). Quantitation of western
blots was accomplished using LabWorks software (UVP).
Electrophoretic mobility shift assay
For generation of the labeled dsRNA probe, complemen-
tary ssRNA oligos (derived from human TTF2 coding
region) were purchased from IDT (Iowa City, IA, USA):
CAAGCAAGAGGCAGAGAUCCCAGGU and ACCU
GGGAUCUCUGCCUCUUGCUUG. These oligos were
then annealed in a 1:1 ratio and 50pmol of dsRNA oligo
were end-labeled with 50pmol of g-
32P-ATP (6000Ci/
mmol, Perkin-Elmer) using 20U of T4 polynucleotide
kinase for 1h at 37 C. Following labeling, the oligo was
puriﬁed using Nuc-Away spin columns (Ambion).
Binding reactions were carried out in 10ml reactions in
25mM HEPES (pH 7.6), 15% glycerol, 60mM KCl,
0.1mM EDTA, 0.1mg/ml BSA, 10mM DTT, 0.01%
NP-40 and 50ng of tRNA non-speciﬁc competitor. The
indicated amounts of each protein were added to the
reactions containing constant amounts of labeled RNA
and were incubated for 15min at room temperature.
Complexes were resolved on a 4% polyacrylamide/
0.5 Tris–glycine native gel and visualized by
autoradiography.
Northern analysis of d7SK
A d7SK anti-sense DNA oligo targeting nucleotides
229–268 (AUACGGCUUCCGGUCGAGACCAGAAU
CCGCGGGGUGGUGG) was purchased from IDT. A
total of 50pmol of oligo were end-labeled with 50pmol
of g-
32P-ATP (6000Ci/mmol, Perkin-Elmer) using 20U of
T4 polynucleotide kinase for 1h at 37 C. Following
labeling, the oligo was puriﬁed using Nuc-Away spin
columns (Ambion). RNA from immunoprecipitations or
from 100ml of glycerol gradient fractions were extracted
using Trizol reagent (Invitrogen), ethanol precipitated and
resuspended in RNA loading buffer. The RNA was then
resolved on a 6% polyacrylamide/1 TBE/6M urea
denaturing RNA gel. Following EtBr staining to visualize
total RNA, the RNA was electro-transferred to NytranN
nylon membrane (Sigma), UV crosslinked to the
membrane and pre-hybridized in UltraHyb (Ambion)
for 2h at 37 C. End-labeled anti-sense d7SK was then
added to the UltraHyb to a ﬁnal concentration of
1 10
6cpm/ml and the membrane was incubated over-
night at 37 C. Finally, the membrane was washed twice
in 2 SSC/0.1% SDS for 5min at room temperature and
once for 5min at 37 C, with subsequent visualization by
autoradiography.
Glycerol gradient ultracentrifugation
Kc cell lysates from 50ml spinner ﬂask cultures at 4 10
6
cells/ml were prepared in 500ml Buffer A [10mM KCl,
10mM MgCl2, 10mM HEPES (pH 7.6), 1mM EDTA,
1mM DTT, 0.1% PMSF, EDTA-free complete protease
inhibitor cocktail from Roche, 20mg/ml E-64, 2mg/ml
Pepstatin A, and 1.5U/ml RNaseOut] containing
150mM NaCl and 0.5% NP-40 as previously described
(31,47). Following incubation on ice for 10min, the
lysates were clariﬁed by centrifugation at 14000rpm for
10min at 4 C in a microfuge. A total of 200ml of the
supernatant was used as input for 4.8ml, 5–45%
glycerol gradients, in Buffer A with 150mM NaCl. The
gradients were spun at 45000rpm for 16h in a SW-55Ti
rotor in a L7-55 Beckman ultracentrifuge and were then
fractionated into 300ml aliquots that were subsequently
analyzed by western or northern blot.
Co-immunoprecipitation of components of the
d7SK snRNP
Antibodies to dLARP7, dHEXIM, or Cyclin T were used
to immunoprecipitate the proteins from Kc cell extracts.
The cells were grown to 90% conﬂuence, harvested,
washed and lysed as for glycerol gradient sedimentation.
Ten micrograms of afﬁnity puriﬁed antibody was then
bound overnight to 50ml of paramagnetic protein
G Dynabeads (Invitrogen) that were blocked and
washed with PBS containing 0.5% BSA. The beads were
then concentrated and resuspended in 200ml of Kc cell
lysate (one T150 ﬂask worth of cells) and incubated with
rotation at 4 C for 2h. After the incubation, the beads
were collected and washed four times with 500ml
immunoprecipitation wash buffer [10mM HEPES (pH
7.6, 150mM NaCl, 2mM MgCl2, 10mM KCl, 0.1%
NP-40, 0.5mM EDTA]. For western analysis, the beads
were suspended in SDS sample loading buffer and heated
to 90 C for 10min and for northern analysis the beads
were subjected to a Trizol extraction.
RNAi-mediated knockdown of dHEXIM in Kc cells
Double-stranded RNAs targeting dHEXIM exons 2 and
3, respectively, were generated by T7 transcription from a
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PCR primers were as follows: exon 2: F 50-GAATTAAT
ACGACTCACTATAGGGAAAGTGGCTCCCAACA
ACGACC, R 50-GAATTAATACGACTCACTATAGG
GATTGATTCTCACGTGATAGTTGGCG; exon 3: F
50-GAATTAATACGACTCACTATAGGGACACTTC
CTCGACCAGCAGCG, R 50-GAATTAATACGACTC
ACTATAGGGATACAATTGGGAGGCGTCGTTTG
CAG. Ten micrograms of each dsRNA was added per
1 10
6 cells and incubated for 72h before making
whole-cell extract. Control cells were incubated with
10ug of LacZ dsRNA per 1 10
6 cells for 72h.
Fly stocks and transgenes for dHEXIM studies
All stocks were maintained and raised under standard
conditions. dHEXIM RNAi transgenic ﬂies used in this
work are provided by the Vienna Drosophila RNAi Center
(VDRC) and by Bloomington Drosophila Stock Center for
all the other strains (rotund-GAL4, engrailed-GAL4,
decapentaplegic-GAL4, patched-GAL4, lozenge-GAL4,
UAS-2EGFP). The speciﬁcity of the dHEXIM RNAi
was conﬁrmed by rescuing the HEXIM developmental
defects with a UAS-HEXIM strain over-expressing
dHEXIM (Table 1 and Supplementary Figure S2).
dHEXIM cDNA isoform A was subcloned in the
pUAST vector (48) and microinjected into embryos
(BestGene). After hatching, the progeny were crossed
with w1118 ﬂies to create transgenic strains. Immuno-
staining of embryos and larvae was performed following
standard procedures. A rabbit polyclonal anti-dHEXIM
antibody was custom made (Genecust) and used at 1:1000
dilution along with a secondary antibody Alexa ﬂuor 488
anti-rabbit (1:200, Invitrogen). Confocal images were
captured on Nikon Eclipse confocal microscopy, and
processed by Adobe Photoshop software. The bin3
mutant ﬂy lines P(SUPor-P)bin3
KG03313 and P(EPgy2)
CG10365
EY08633 were obtained from the Bloomington
Stock Center. The balancers were changed to appropriate
green balancer chromosomes (CyO or TM3 bearing
actin-GFP transgenes) for scoring non-green homozygous
mutant larvae for the northern blot analysis.
Kinase assay
Assays were performed as described earlier(3) except that
human DSIF was used as substrate, reaction time was
15min and the label was 20mM
32P-ATP. 7SK snRNP
immunoprecipitations were carried out as described
above except that beads were washed with 150mM KCl,
25mM HEPES (pH 7.6), 0.02% Tween20 and 50U/ml
RNAseOut. After the ﬁnal wash the beads were resus-
pended in kinase reaction buffer (-ATP), treated or not
for 10min with 10mg of RNaseA and then the reaction
was started with the addition of ATP. The samples were
analyzed by SDS PAGE followed by drying of the gel. The
results were quantiﬁed using a phosphorimager (Fuji
FLA7000).
dLARP7 immunoﬂuoresence
Fly tissues were processed for immunoﬂuorescence
microscopy following the standard procedure. In brief,
dissected wild type third instar larval tissues and adult
ovaries were ﬁxed in 4% paraformaldehyde, washed
several times with 1 PBS and permeabilized with 1%
Triton X-100 for 10min. After two washes in 1 PBS,
samples were blocked for 1h with 5% NGS in 1 PBS
followed by incubation overnight at 4 C with the primary
antibody at 1:100 dilution. Signal was detected using sec-
ondary antibody conjugated to Alexa-594. Images were
captured using Leica TCS SP5 confocal microscope.
RESULTS
Identiﬁcation and characterization of dHEXIM
P-TEFb comprised of Cdk9 and Cyclin T was originally
identiﬁed in Drosophila (2,34,49), but because it was not
clear if a large inhibited form of P-TEFb existed in ﬂies,
we ﬁrst searched for potential homologs of the key human
inhibitors, HEXIM1 and HEXIM2. A BLAST search
identiﬁed, two alternative-splicing isoforms of a single,
previously uncharacterized gene (CG3508) that contained
signiﬁcant similarity to HEXIM1 (28% identical and 46%
conserved) and HEXIM2 (27% identical and 45%
Table 1. Rescue of RNAi-mediated HEXIM loss phenotypes by co-overexpressing HEXIM cDNA (29 C)
UAS-HEX RNAi UAS-HEX; UAS-HEX RNAi
Driver Domain of expression Developmental defects Rescued phenotypes
Rotund
a Wing, leg, antenna, haltere discs 100% undeveloped wings (n=148) 22% undeveloped wings (n=810)
100% undeveloped legs 10% undeveloped legs
0% wild type 78% wings & 90% legs wild type
Lozenge
b Eye discs 95.8% lethal pupae (n=227) 8.1% lethal pupae (n=222)
4.2% viable with mutant eyes 14.9% viable with mutant eyes
0% wild type 77% wild type
GMR Eye discs 44.2% black-spotted eyes (n=129) 2% black-spotted eyes (n=216)
55.8% rough eyes 48.5% rough eyes
0% wild type 49.5% wild type
Patched Early segmental domains
of embryos; wing, leg discs
100% lethal Larvae stage 2 (n=73) 25.4% lethal Larvae stage 2 (n=252)
0% viable 74.6% viable
aThe percentages of developmental defects of halteres and antenna were similar to that of wing appendages.
bThe crosses were preferably done at 25 C in order to optimize the mating conditions due to the characteristics of Lozenge strain. All the same
mutant phenotypes were also recorded at 29 C.
n=total number of ﬂies counted for each experiment.
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protein containing the important KHRR RNA-binding
domain, as well as the PYNT and SDVYER (SETYER
in humans) sequences required to bind and inhibit the
kinase activity of P-TEFb (29,50) (Figure 1A). To
generate tools for biochemical analyses of this protein,
the larger isoform of the gene, renamed dHEXIM, and a
KHRR to ILAA mutation known in human HEXIM1 to
abrogate RNA-binding (29), were subsequently expressed
in E. coli and puriﬁed (Figure 1B). Sheep polyclonal
antibodies were generated to and afﬁnity-puriﬁed using
the wildtype protein. These antibodies recognized both
the recombinant dHEXIM and a similarly sized protein
in Kc cell extracts (Figure 1C). This suggests that the
putative Drosophila homolog of HEXIM1 is indeed
expressed in vivo and may be involved in controlling
P-TEFb.
To determine whether or not dHEXIM might be
involved in controlling P-TEFb using the same mechanism
as human HEXIM1, we ﬁrst investigated whether or not it
is a general dsRNA-binding protein like HEXIM1 (51).
An electrophoretic mobility shift assays (EMSAs) was
used to monitor RNA-binding. Puriﬁed recombinant
wild-type (WT) dHEXIM or the RNA-binding mutant
(ILAA) was titrated into reactions containing a constant
amount of labeled dsRNA oligo. After 10min incubation,
the complexes were resolved on a Tris–glycine native
gel and visualized by autoradiography (Figure 2A).
As wild-type dHEXIM was titrated into the reaction,
there was a concomitant increase in a single band of
decreased mobility in the gel, representing the
dHEXIM RNA complex. In contrast, when equal
amounts of mutant dHEXIM were assayed, there was
no observable complex formation. These results demon-
strate that dHEXIM is also a general dsRNA-binding
protein, and that, like the human HEXIM proteins, the
KHRR domain is required for this binding.
To determine if dHEXIM and P-TEFb are normally
found associated with RNA in vivo, glycerol gradient ultra-
centrifugation analysis was performed on a Kc cell lysate
that was treated or not with RNase A (Figure 2B).
Figure 2. Characterization of dHEXIM. (A) EMSA with dsRNA and
recombinant dHEXIM proteins. The indicated amounts of wildtype
(WT) and KHRR to ILAA mutant dHEXIM were incubated with
labeled dsRNA and analyzed on a native gel as described in
‘Materials and Methods’ section. (B) Glycerol gradient analysis of
control and RNase A treated Kc cell extracts. A Kc cell lysate was
prepared and analyzed by glycerol-gradient sedimentation as described
in ‘Materials and Methods’ section. Half of the lysate was treated with
RNase A and the other half served as a control. Gradients were
fractionated from the top so that increasing fraction number correlates
with increasing particle size. Aliquots of each fraction were subjected to
western blotting with the indicated antibodies. (C) Quantiﬁcation of
signals in (B).
Figure 1. Puriﬁcation of recombinant dHEXIM and detection of en-
dogenous dHEXIM. (A) Diagram showing the location of regions
highly conserved between human HEXIM1 and Drosophila HEXIM
(dHEXIM). (B) Silver-stained SDS PAGE analysis of wildtype (WT)
and RNA-binding domain mutant (ILAA) of HEXIM1 and dHEXIM.
(C) western blot analysis of recombinant dHEXIM expressed in E. coli
(Ec) and in endogenous dHEXIM in Kc cells (Kc) probed with afﬁnity
puriﬁed anti-dHEXIM antibody.
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was performed for both Cyclin T and dHEXIM. In the
absence of RNase (control), there were two forms of
P-TEFb with about half of the P-TEFb in the larger mo-
lecular weight fractions (fractions 11–16). A distribution
of sizes were also found for dHEXIM; a smaller molecular
weight peak (fractions 5–8), and a larger molecular weight
peak (fractions 9–13) that overlapped, but did not com-
pletely co-fractionate, with the large form of P-TEFb.
Upon treatment with RNaseA, P-TEFb shifted up the
gradient to smaller size strongly suggesting that the large
form of P-TEFb was an RNP. Interestingly, ribonuclease
treatment had a less profound effect on the sedimentation
of dHEXIM. Quantiﬁcation of the distribution of Cyclin
T and dHEXIM for the four gradients demonstrated that
most of the P-TEFb, but only  10% of the dHEXIM
shifted to the smaller forms after ribonuclease treatment
(Figure 2C). It is not clear if the large form of dHEXIM
that remains after ribonuclease treatment is due to oligo-
merization of dHEXIM or association with other
proteins. However, after ribonuclease treatment almost
all of the high-molecular weight dHEXIM is in fractions
without P-TEFb, therefore as found in humans
the HEXIM P-TEFb interaction requires RNA. The
glycerol gradient results suggest much of the P-TEFb
and a small but signiﬁcant fraction of dHEXIM is
normally bound to RNA.
Identiﬁcation of a LARP7 Homolog, dLARP7
Our attention turned next to the identiﬁcation of a
Drosophila homolog for LARP7, an RNA-binding
protein that plays an important role in the human 7SK
snRNP (18). The gene identiﬁed by a simple bioinformatic
search as the potential homolog was initially called multi
sex combs (MXC). Genetic analysis of MXC
demonstrated that it was a Polycomb Group protein
that was important in development and when mutated
caused cancerous transformation of blood cells (52).
However, recently, MXC was reassigned to an adjacent
gene and the LARP7 homolog was renamed CG42569.
The potential LARP7 homolog is 22% identical and
45% similar to the human protein and has an identical
domain organization with a La motif and two RNA-
binding motifs (RRMs) (Figure 3A). A cDNA encoding
the full-length protein was expressed in E. coli; however,
only a C-terminal proteolysis product was puriﬁed using
the C-terminal His tag. An antibody was produced in
sheep and afﬁnity puriﬁed. This antibody recognized one
major band on a western blot of whole cell or nuclear
extracts from Kc cells (Figure 3B). It was not unexpected
that the apparent molecular weight of the protein
recognized (90kDa) was larger than that predicted
(67kDa) because it is highly charged.
Glycerol-gradient sedimentation was performed on Kc
cell lysates to examine the size of complexes containing
the potential LARP7 homolog. As was done for
dHEXIM the cell lysate was either treated with RNase
A or left untreated as a control. Antibodies to cyclin
T gave the expected patterns demonstrating an RNA
dependence on high-molecular weight P-TEFb complexes.
The antibodies against the putative LARP7 homolog gave
patterns that indicated that almost half of the protein was
in the same region of the gradient as the large form of
P-TEFb. This material sedimented more slowly after
RNase treatment. The sequence similarity to human
LARP7 and the co-sedimentation with P-TEFb in an
RNase sensitive complex, justiﬁes renaming the gene,
LARP7, and the protein, Drosophila LARP7 or dLARP7.
Characterization of d7SK
A key component of the large P-TEFb complex is the
structural RNA, 7SK (19). Standard bioinformatics
approaches to identify Drosophila 7SK were not success-
ful. However, a putative arthropod 7SK was proposed by
Gruber et al. (46), based on the presence of a Pol III
promoter elements and structural modeling of the 50-
and 30-ends of the transcript (46). Based on the sequence
similarity of this gene within many Drosophila species, it
appears that this gene encodes a 444nt RNA (Figure 4A).
Interestingly, this RNA begins and ends identically
to the human 7SK RNA (GG and UUCUUUU, re-
spectively), and, furthermore, contains two AUCUG
sequences separated by 8nt, exactly like human 7SK
(37) (Figure 4B, underlined sequences).
The association of the potential Drosophila 7SK (d7SK)
with dLARP7 and dHEXIM was examined to gather
evidence that it was indeed a part of the large inactive
P-TEFb complex. First, immunoprecipitation of LARP7
from Kc cell extracts was carried out and the RNA that
was bound and unbound to the antibody beads was
analyzed on a denaturing gel. Ethidium bromide staining
demonstrated that an RNA that ran between the 500 and
800nt marker was speciﬁcally pulled down (Figure 4C). A
smaller RNA ( 300nt) was also present, but a large
amount of similarly sized RNA was present in the
unbound fraction with many other unbound RNAs sug-
gesting that the smaller RNA was recovered in the bound
fractions due to a weak or non-speciﬁc association. The
bound and unbound fractions were then subjected to
northern blotting using a probe designed from the
proposed 7SK. A band of identical size to the large
RNA pulled down was detected only in the bound
fraction (Figure 4C). We were initially concerned by the
apparent large size of the RNA identiﬁed, but a 444nt
RNA generated by in vitro transcription of the d7SK
gene had a similar aberrant mobility (data not shown).
This is likely due to the predicted very high structure
content of the RNA which is not completely removed in
the TBE/Urea gels used. To determine if dHEXIM would
bind to d7SK, labeled in vitro transcribed RNA was used
in an RNA mobility shift assay. As increasing amounts of
dHEXIM were incubated with the RNA, an RNA protein
complex was correspondingly detected in the gel
(Figure 4D). Association of 7SK with dLARP7 in vivo
and dHEXIM in vitro strongly suggests that d7SK was
identiﬁed correctly.
To determine if P-TEFb, dHEXIM, dLARP7 and
d7SK were all present in the same complex immunopreci-
pitations from Kc cells extracts with antibodies to each of
the proteins were performed (Figure 4E). Signiﬁcantly,
Nucleic Acids Research, 2012,Vol.40, No. 12 5289Figure 4. Characterization of the Drosophila 7SK snRNP. (A) Drosophila 7SK gene. The diagram shows the Pol III promoter driving 7SK RNA.
The track below the diagram shows conservation of the region across all Drosophila species (from UCSC Genome Browser). (B) Sequence of 7SK
RNA. Underlined nucleotides denote a region that is highly conserved between human and Drosophila 7SK. (C) Association of 7SK with LARP7. As
described in ‘Materials and Methods’ section, the afﬁnity puriﬁed LARP7 antibody was used to pull down LARP7 complexes and the RNA found in
the bound ‘B’ and unbound ‘UB’ fractions was detected on a denaturing gel by ethidium bromide staining and by northern blot. (D) EMSA of 7SK
RNA with dHEXIM on native gel as described in ‘Materials and Methods’ section. (E) Immunoprecipitation analysis of 7SK snRNP. Antibodies
against HEXIM ‘H’, LARP7 ‘L’ and Cyclin T ‘C’ were used in immunoprecipitate the proteins from Kc cell extract. Western blots using the
indicated antibodies were used to probe the bound and unbound material from each immunoprecipitation. A northern blot of similar fractions from
another set of immunoprecipitations (denoted by an asterisk) was used to examine the presence of 7SK. The immunoprecipitations were not as
efﬁcient for this set of reactions. (F) Kinase assay with DSIF substrate. P, P-TEFb; C, Control 7SK snRNP; R, RNaseA treated 7SK snRNP; D,
50mM DRB. The experiment shown in lanes 3–6 was repeated three times giving an average 1.8-fold stimulation with RNaseA.
Figure 3. Characterization of dLARP7. (A) Diagram showing the location of regions highly conserved between human LARP7 and Drosophila
HEXIM (dLARP7). (B) Western blot analysis of endogenous dLARP7 in Kc cell whole-cell (W) and nuclear (N) extract probed with afﬁnity puriﬁed
anti-dLARP7 antibody. Arrow indicates dLARP7. (C) Glycerol-gradient analysis of control and RNase A treated Kc cell extracts. A Kc cell lysate
was prepared and analyzed by glycerol gradient sedimentation as described in ‘Materials and Methods’ section. Half of the lysate was treated with
RNase A and the other half served as a control. Gradients were fractionated from the top so that increasing fraction number correlates with
increasing particle size. Aliquots of each fraction were subjected to western blotting with the indicated antibodies.
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7SK. dLARP7 antibodies pulled down Cyclin T and 7SK.
dHEXIM was not detected due to the small fraction of
dHEXIM bound to 7SK and to interference with detec-
tion by heavy chain antibody in that region of the gel.
Cyclin T pulled down dLARP7, and 7SK, but again
dHEXIM was not detected. These immunoprecipitation
results are consistent with the existence of a Drosophila
7SK snRNP containing P-TEFb, dHEXIM, dLARP7
and d7SK.
Finally, to conﬁrm that P-TEFb was held in an
inactive state when associated with the 7SK snRNP, a
kinase assay was performed. As expected, Drosophila
P-TEFb phosphorylated DSIF in a DRB-sensitive
manner (Figure 4F, lanes 1, 2). 7SK snRNP was immu-
noprecipitated using LARP7 antibodies from fractions
11–14 of the control glycerol gradient shown in
Figure 2B. Reactions containing equal amounts of the
7SK snRNP were assayed with and without RNaseA
treatment in the absence and presence of DRB. A repre-
sentative of three replicates shown in Figure 4F (lanes 3–6)
demonstrates an activation of P-TEFb by RNaseA.
Kinase activity was increased an average of 1.8-fold
(±0.3). This fold activation is somewhat low due to a
small amount of free P-TEFb in that region of the
gradient (Figure 2B; RNaseA).
Functional characterization of the Drosophila 7SK snRNP
Since treatment of human cells with P-TEFb inhibitors
leads to release of P-TEFb from the 7SK snRNP,
glycerol-gradient analysis of Kc cells before and after
treatment with either DRB or ﬂavopidirol was performed
to further characterize the properties of the d7SK snRNP.
The gradients were probed using westerns for Cyclin T,
dHEXIM and dLARP7, and using northerns for 7SK
(Figure 5). As shown earlier, Cyclin T was found in two
peaks across the gradient, a small form (fractions 5–9) and
a large form (fractions 10–14). dLARP7 displayed broad
sedimentation with a clear peak in fractions 11 and 12.
dHEXIM was again also found in two regions of the
gradient. In contrast, d7SK was found in a single region
of the gradient, the majority of which peaked in fractions
11 and 12 with Cyclin T, and dLARP7.
Identical glycerol-gradient analyses were performed
after treatment of Kc cells for 1h with either DRB or
ﬂavopiridol to inhibit P-TEFb (Figure 5B and C). Upon
treatment with either drug there was a dramatic shift of
P-TEFb as detected by Cyclin T to the small form
(fractions 5–9) as it was released from the d7SK snRNP.
The most rapidly sedimenting (largest) dHEXIM
shifted up the gradient one fraction, as was observed
during the RNase treatment, again supporting the hypoth-
esis that at least some of the dHEXIM is in the
d7SK snRNP. As expected, the small form of dHEXIM
did not shift signiﬁcantly up the gradient. d7SK and
dLARP7 did not display a shift in sedimentation after
the treatments as has been found for the human
7SK and LARP7 because human LARP7 is always
found associated with 7SK. Because dHEXIM and
P-TEFb were observed to leave the complex, this
suggests that they are replaced by other proteins that
keep the d7SK in the same position within the gradient,
consistent with acquisition of hnRNPs as is found in
humans (27).
To conﬁrm that dHEXIM is required for the recruit-
ment of P-TEFb into the 7SK snRNP, the effect of
knocking down dHEXIM in Kc cells was examined.
RNAi was used to knockdown either LacZ as a negative
control or dHEXIM before cell lysates were analyzed by
glycerol gradient sedimentation. The knockdown was
efﬁcient as indicated by a western blot of cell lysates
(Figure 5D, left panel). In control cells the normal
pattern was observed for Cyclin T (Figure 5D, upper
right panel), but after knockdown of dHEXIM all of the
P-TEFb shifted to smaller size (Figure 5D, lower right
panel). This experiment demonstrates that the large form
of P-TEFb is dependent on dHEXIM.
Figure 5. Glycerol gradient analysis of lysates from Kc cells treated
with P-TEFb inhibitors or HEXIM siRNA. Treatments and generation
of lysates is described in ‘Materials and Methods’ section. Antibodies
used in westerns are indicated. (A) Control cells. (B) Cells treated with
Flavopiridol for 1h. (C) Cells treated with DRB for 1h. (D) Effect of
knockdown of dHEXIM. Kc cells were treated with RNAi to lacZ ‘L’
as a control or dHEXIM ‘H’ and equal amounts of SDS lysed cells
were analyzed by western blot using the dHEXIM antibody. Cell
lysates were also prepared and analyzed by glycerol-gradient sedimen-
tation and western analysis using antibodies to Cyclin T.
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The results described above indicate that Drosophila Kc
cells express P-TEFb, dHEXIM dLARP7 and d7SK and
these components are assembled into a d7SK snRNP. To
extend these results into a physiologically relevant system,
we ﬁrst examined the expression of dLARP7 in whole ﬂies.
Consistent with the expected global role for the 7SK
snRNP, dLARP7 was expressed at all developmental
stages, both in diploid and polyploid tissues (Figure 6).
Irrespective of this expression all through development,
certain differences in dLARP7 expression are noteworthy.
For example, dLARP7 was expressed predominantly in
the ommatidial cluster of the eye disc, while expression
in the rest of the eye and antennal discs was signiﬁcantly
reduced (Figure 6A). Similar is the case with the wing disc,
wherein, including the wing pouch, there was no signal
detected above background for dLARP7, except in a
cluster of cells in the notum region (Figure 6A).
Wherever expression was observed, the protein was
always localized to the nucleus, though the intra-nuclear
distribution varied depending on the cell type (Figure 6).
For example, dLARP7 was pan-nuclear, excluding
nucleoli, in larval salivary glands and fat bodies. In
contrast, predominant nucleolar localization was found
in the cells of gut and gastric caecae (Figure 6B).
Because LARP7 is a required partner of 7SK in humans
and levels of dLARP7 are variable in different tissues, it is
likely that the level of the d7SK snRNP is regulated in a
biologically signiﬁcant way.
dHEXIM is necessary for proper ﬂy development
dHEXIM is continuously and ubiquitously expressed
during embryogenesis (Figure 7A). A tight correlation
between the expression patterns of dHEXIM protein
and HEXIM mRNA was detected by in situ hybridization
(data not shown). Of note, there was a strong accumula-
tion of dHEXIM before the zygotic expression (stages
1–3) indicative of a maternal origin. The strong and ubi-
quitous dHEXIM expression persists to latter stages
(i.e. third instar larvae) in all the tested tissues and
organs (Figure 7B). Importantly, HEXIM is predomin-
ately localized in the nucleus, which is consistent with its
role in regulation of transcription and with the localiza-
tion of the d7SK snRNP.
To determine the requirement of dHEXIM in embryo-
genesis, early development and in the adult, the effects of
tissue-speciﬁc knockdown of dHEXIM were examined.
Knockdown was carried out using the GAL4 enhancer
trap system that generates tissue-speciﬁc RNAi (48). To
this end, UAS-dHEXIM RNAi lines (53) were crossed
with lines driving GAL4 expression to a speciﬁc tissue
and/or developmental stage. UAS-GFP lines, expressing
GFP under the control of the GAL4 promoter, were used
as a control to visualize the proper expression domain of
the GAL4 driver (Figure 7C, left panel). As expected,
dHEXIM expression was speciﬁcally reduced in the
areas of the GAL4 driver expression domain (Figure 7C,
right panel). dHEXIM knockdown was further conﬁrmed
by western blot analysis on the same ﬂies (data
not shown). Moreover, dHEXIM knockdown was
systematically rescued by dHEXIM cDNA over-
expression (Table 1 and Supplementary Figure S1), thus
unambiguously showing the speciﬁcity of dHEXIM
knockdown. Of note, given that dHEXIM can bind
dsRNA and that >90% of dHEXIM is unbound (to the
7SK snRNP), we cannot exclude that the RNAi pheno-
types could be partly due to the disruption of additional
interactions of dHEXIM with yet-to-be discovered RNAs,
other than the 7SK.
dHEXIM knockdowns carried out with the ubiqui-
tously expressed actin- or tubulin-GAL4 drivers were
lethal, with development stopping by the third instar
larval stage. A collection of GAL4 drivers (engrailed-
GAL4, decapentaplegic-GAL4, patched-GAL4), which
have a more restricted expression pattern during embryo-
genesis, also led to developmental arrest, but at earlier
times (embryogenesis or ﬁrst or second instar larvae).
When dHEXIM knockdown was targeted to a speciﬁc
region of any imaginal disc, the corresponding tissue sys-
tematically failed to develop properly and was often
missing at the adult stage (Figure 7D and data not
shown). For example, when dHEXIM RNAi is driven
by rotund-GAL4 (expressed in wing and haltere pouch,
center of leg, and antenna imaginal discs), adult ﬂies
harbored strongly atrophic wings, halteres, legs and
antennae. Strikingly, the lozenge-GAL4 driver (expressed
in eye-antennal discs) induced headless pharate adults
which died during the eclosion process (Figure 7D).
More than 10 different organogenesis-speciﬁc drivers
have been tested and all resulted in developmental arrest
or organ defects dependent on the temporal and spatial
expression of the corresponding GAL4 drivers. These
results demonstrate that dHEXIM is a crucial factor
required, in particular, for the proper organ formation,
and in general for the entire organism development.
DISCUSSION
We have provided strong evidence that the 7SK snRNP
which has been demonstrated to control P-TEFb in
mammals is also expressed in Drosophila. Bioinformatic,
biochemical and molecular genetic methods led to the
identiﬁcation of a P-TEFb complex containing homologs
of HEXIM1/2, LARP7 and 7SK. The d7SK snRNP
responds to inhibition of P-TEFb in an immortal cell
line by release of P-TEFb and dHEXIM suggesting that
it is regulated by similar mechanisms as found in humans.
Importantly, having identiﬁed most of the components of
the d7SK snRNP and developed molecular probes for the
proteins and RNA, allows for the complex to be studied
during the development of an organism. Toward that end,
we demonstrated that components are expressed in a
variety of tissues and embryonic developmental stages.
Signiﬁcantly, the key P-TEFb regulator, dHEXIM, is
essential for proper Drosophila development.
The fact that the various components of the
7SK snRNP complex are found in both Drosophila and
human is unlikely the result of convergent evolution.
Rather, this strongly suggests that the complex
characterized in this work is a true homolog of the one
5292 Nucleic Acids Research, 2012,Vol.40, No. 12Figure 6. Expression proﬁle of dLARP7 during ﬂy development. All panels show immunoﬂuorescence using confocal microscopy and antibodies to
dLARP7 (red) individually or merged with DAPI staining (blue). (A) dLARP7 is differentially expressed in the larval eye-antennal and wing discs.
AD, antennal disc; NT, notum; WP, wing pouch. The ommatidial cluster of the eye disc is demarcated by a dashed line and zoomed in the lower
panel. (B) dLARP7 is nuclear localized in the larval tissues. Nuclei in the indicated tissues are shown. Arrow heads indicate nucleoli. The inset in the
merged image from the Gut shows just the DNA staining of the dashed region to highlight the nucleoli (arrow). (C) Nuclear localization of dLARP7
in the adult ovarian egg chamber.
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that the ﬂy 7SK snRNP complex is sensitive to P-TEFb
inhibitors in a manner similar to that of human’s. Thus,
one would expect the complex to have similar biological
function in both Drosophila and human at the molecular,
cellular and developmental level.
Although we were able to draw many similarities
between the human and Drosophila 7SK snRNP, there
were some differences found. Most of the detailed work
on the 7SK snRNP in humans has been carried out in
HeLa cells, and here, we described the biochemical char-
acterization of complexes obtained from the Kc cell line.
Both cell lines are immortal and have similar doubling
times. As was found in the human system, P-TEFb is in-
hibited by the 7SK snRNP. Both human HEXIM1 (51)
and dHEXIM (Figures 1 and 2) have the ability to bind to
small dsRNAs in addition to 7SK. In HeLa cells,  80%
of HEXIM1 is found in a low molecular weight form
out of the 7SK snRNP, and in Drosophila, 90–95% of
dHEXIM is not in the d7SK snRNP. A difference is
that most of the ‘free’ dHEXIM is found in a high
molecular weight form that is slightly smaller than the
7SK snRNP. We do not know the nature of the rapidly
sedimenting form of dHEXIM, but based on a number of
Figure 7. Expression proﬁle and knockdown of HEXIM during development. (A) Immunostaining of dHEXIM during embryogenesis using
confocal microscopy. Developmental stages are indicated on each panel. All embryos are oriented anterior to the left, dorsal uppermost. (B)
Immunostaining of dHEXIM during organogenesis (third instar larvae). Top left to bottom right: wing disc, eye-antennal discs, brain and ring
gland, leg disc, fat bodies and salivary glands. (C) The expression domain of the rotund-GAL4 driver (rn-GAL4) is revealed by GFP signal in third
instar wing and leg discs (left column), and the expression pattern of dHEXIM in wing and leg discs expressing dHEXIM RNAi under the control of
the rotund-GAL4 driver (right column). (D) Mutant phenotypes of dHEXIM knockdown with rotund-GAL4 and lozenge-GAL4 (lz-GAL4). In
dHEXIM
  leg, most of the tarsal segments from 1 to 5 are missing, thus leading to much foreshortened legs (left column). dHEXIM
- wing is strongly
atrophied and crumpled (middle column). dHEXIM
  pharates (right column) are headless and fail to progress to adult stage.
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it is not part of the 7SK snRNP. In both organisms, all
7SK is bound by LARP7 (21)(Figure 4C), but only in
Drosophila is some free LARP7 found (Figure 5). What
role LARP7 might play out of the 7SK complex is not
clear (Figure 3). Treatment of human (18) or Drosophila
(Figure 5) cells with P-TEFb inhibitors leads to release of
P-TEFb and HEXIM. While it has been determined that
human 7SK undergoes a conformational change upon loss
of P-TEFb and HEXIM1 (38), this has not been examined
for d7SK. However, the main structural elements of
human 7SK are found in d7SK including two highly
conserved regions that predict that the 5’-end of the
RNA would pair with a region just upstream of the ﬁnal
stem and loop that is required for P-TEFb association
with the 7SK snRNP (18,19).
Bin3, the Drosophila homolog of the human methyl
phosphate capping enzyme (MEPCE) that methylates
the gamma phosphate at the 50-end of 7SK (21,25,54)
was recently demonstrated to be required for the stability
of d7SK (26). We performed a similar analysis on ﬂies’
mutant for Bin3 and found that mutation of Bin3 lead to
destabilization of d7SK without affecting U6 snRNA that
is capped in a similar manner to 7SK snRNA
(Supplementary Figure S2). Bin3 was discovered as a
protein that interacted with Bicoid, a homeodomain
protein that directs early pattern formation (55). Besides
playing a role in stabilizing d7SK, Bin3 was found in a
complex with bicoid on the 30-UTR of the caudal mRNA
(26). It will be interesting to determine if Bin3’s role in
repressing translation of caudal mRNA is related to its
role in the d7SK snRNP.
It is of interest that dLARP7 showed differential
intra-nuclear distribution in a tissue-speciﬁc manner. In
tissues like larval salivary glands, fat bodies and the
adult ovary, dLARP7 displayed pan-nuclear localization,
excluding nucleoli as is found for LARP7 in HeLa cells
(22) (Supplementary Figure S3). In contrast, in the larval
gut and gastric caecae, it localizes predominantly to the
nucleoli, with diffuse staining in the nucleoplasm. Similar
intra-nuclear localization was reported for the mammalian
7SK RNA, though the exact reason for the observed
discrepancy is not clearly understood. For example,
while a number of groups have showed that 7SK
is pan-nuclear, colocalizing with splicing factor compart-
ments (56,57,58), the work from the Zhou lab (59) showed
that a majority of nuclear 7SK is localized to the nucle-
olus. While this discrepancy could be due to the age of the
culture or the culture conditions applied, it is implicit in
these data that the localization of 7SK snRNP is dynamic
and might change in response to developmental and
physiological needs. Accordingly, dLARP7 also showing
these localizations trends reminiscent of 7SK snRNP
suggests a greater biological meaning to differential ex-
pression and localization.
What have we learned about the involvement of the
7SK snRNP in Drosophila development? Although some
tissues seem to have more or less dLARP7 and
dHEXIM, both are ubiquitously expressed. Variation in
expression may relate to the amount of the 7SK
snRNP that is needed for each tissue to supply P-TEFb
for its transcriptional program. The most important
ﬁnding was that dHEXIM is absolutely essential for
survival of the embryo and is required for development
of all tissues tested. When knocked down early embryos
fail to progress past the larval stage. When the early re-
quirement is bypassed by expressing siRNA later in
speciﬁc tissues, every tissue targeted was dramatically
affected yielding severe phenotypes. Our results support
the idea that regulation of P-TEFb plays a critical role
in Drosophila development which ﬁts with the recent
ﬁndings indicating that genes controlling development
are usually loaded with polymerases poised for the
P-TEFb-mediated transition into productive elongation
(42,60).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Figures S1–S3.
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